Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01251263
Other study ID # 90304
Secondary ID
Status Recruiting
Phase Phase 4
First received November 30, 2010
Last updated November 30, 2010
Start date October 2010
Est. completion date October 2012

Study information

Verified date October 2010
Source Scott and White Hospital & Clinic
Contact Wendy M White, CCRP
Phone 254-724-8301
Email wewhite@swmail.sw.org
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study will examine the combined effects of a continuous oral contraceptive (OC) regimen with supplemental estradiol therapy on headache severity and occurrence in subjects with documented Menstrually Associated Migraines (MAMs). The subjects enrolling in the study will have cyclic menses either due to spontaneous ovulation or use of cyclic hormonal contraception (pill, patch, or ring). Enrolled subjects will start a continuous OC regimen following two baseline menstrual cycles. If breakthrough bleeding/spotting (BTB/BTS) occurs, the subject will institute a 4-day hormone-free interval (HFI). In an attempt to prevent/lessen the severity of headache during the HFI, subjects will be randomized to oral estradiol or placebo during this period. If no BTB/BTS occurs after 80 days of continuous pills, the subject will institute a 4-day HFI during which they will be randomized into estradiol or placebo groups.

The purpose of this research study is to examine the effects of continuous oral contraceptive pills and oral estradiol on headaches that occur around the time of your period. Many woman take continuous oral contraceptive pills (OC) and when OCs are stopped they may get headaches. This study will examine if taking estradiol around the time of the period will affect the headache, and how it will be affected.

This study is a prospective trial. A subject's participation will last approximately 32 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Women may be on birth control pill (OC), patch or vaginal ring taken in the traditional 21/7 or 24/4 manner, which means that every month they have a period. If they are taking it continuously (without a period), you must be willing to take your birth control 21/7 for 2 months.

- If you are not on OC's, patch or vaginal ring you must have a period every 21-40 days.

- You must not want to get pregnant for 12 months.

- Women who have headaches around the time of their period.

Exclusion Criteria:

- BMI >38

- If you smoke and are age 35 years old or greater or if you are under 35 years old and smoke over 10 cigarettes a day.

- If you have or had an aura with your headaches. (An aura is a temporary sensation, like bright lights that come before you experience the headache)

- Headaches are not occuring during the time of your period.

- Blood Pressure > 140/90 or you take more than a single antihypertensive medication (excluding diuretics) and are age 40 or greater.

- Contraindications to combination estrogen/progestin hormonal contraceptives.

- Desire to become pregnant in the next 12 months.

- Stroke

- Breast Cancer

- Blood clots in your legs, lung or anywhere else in your body.

- Diabetes Mellitus

- Heart Attack

- Liver Disease

- Systemic Lupus Erythematosus

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Estradiol or Placebo
Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
Estradiol or Placebo
Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)

Locations

Country Name City State
United States Scott and White Hospital & Clinic Temple Texas

Sponsors (1)

Lead Sponsor Collaborator
Scott and White Hospital & Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Outcome Measure Comparing baseline menstrually associated migraines(MAMs) to headache occurance and severity after the implementation of continuous OC therapy. 32 weeks No
Secondary Secondary Outcome Measure Compare effect of estradiol versus placebo on MAMs severity and duration. 32 weeks No